Record Cash Flow Fuels Strategic Shift to Clinical Search AI (DOCS Q4 2026 Earnings Call)
Export as clean Markdown. Drag & drop into ChatGPT, Claude, or Gemini.
Doximity recorded its first ever nine-digit free cash flow quarter and exceeded the high end of its revenue guidance, paving the way for the company to aggressively monetize its clinical Search and Scribe artificial intelligence platform.
Record Free Cash Flow Caps Strong Full Year Top-Line Performance
Doximity reported fourth quarter revenue of $145 million, exceeding the high end of its guidance because existing pharmaceutical customers expanded their marketing campaigns. This strong finish contributed to a total full year revenue of $645 million, reflecting double-digit annual growth driven by steady core subscription renewals. High operating efficiency enabled Doximity to generate a record $107 million in fourth quarter free cash flow, representing its first ever nine-digit cash flow quarter.
Increased AI Compute Spending Prioritizes Platform Innovation
For the upcoming fiscal year, Doximity expects annual revenue between $664 million to $676 million due to policy uncertainty in the digital advertising market. To support its platform transformation, the company projects full year adjusted EBITDA to range from $323 million to $335 million because of near-term margins pressure. Additionally, stock-based compensation will rise to the low 20s as a percentage of revenue to reward the newly expanded engineering team.
Active Prescriber Growth Accelerates Doximity Workflow Platform Usage
Doximity finished the fiscal year with an impressive net revenue retention rate of 109% because pharmaceutical brands steadily increased their platform budgets. Clinicians also adopted the platform at a faster rate, driving unique active quarterly prescribers to over 800,000 unique users. In clinical trials, surveyed resident physicians chose Doximity AI search results over competitors by a 2:1 margin because of its peer-reviewed accuracy.
Enterprise AI Monetization Taps Into Massive Paid Search Budgets
Doximity accelerated its long-term clinical strategy by acquiring Pathway for $63 million last summer. Pharma executives showed strong interest in the commercial launch because many have top-down mandates requiring 10% to 20% of their ad budgets to be spent on artificial intelligence. This commercialization strategy positions Doximity to capture a meaningful share of the massive $19 billion paid search market.